Pomalidomide therapy for multiple myeloma and myelofibrosis: An update

Leukemia and Lymphoma

Volumn 52, Issue 4, 2011, Pages 560-566

  Lacy, Martha Q ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

multiple myeloma; myelofibrosis; Pomalidomide

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; POMALIDOMIDE;

ACUTE LUNG INJURY; CANCER RELAPSE; DRUG DOSE ESCALATION; DRUG TOLERABILITY; ERYTHEMA NODOSUM LEPROSUM; HUMAN; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; THROMBOEMBOLISM; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE MYELOMA; PRIMARY MYELOFIBROSIS; PROTEASE INHIBITORS; PYRAZINES; THALIDOMIDE;

EID: 79953197227     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.552139     Document Type: Review

References (61)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [see comments]. N Engl J Med 1999;341:1565-1571.
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-2520.
4. von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al. A systematic review of phase II trials of thalidomide/dexametha-sone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 2008;81:247-252.
5. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-2132. (Pubitemid 350146107)
6. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142. (Pubitemid 350146108)
7. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study ofbortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617. (Pubitemid 36741588)
8. Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, velcade and dexa-methasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 2007;92:1149-1150. (Pubitemid 350144228)
9. Kropff M, Bisping G, Schuck E, et al. Bortezomib in com-bination with intermediate-dose dexamethasone and contin-uous low-dose oral cyclophosphamide for relapsed multiple myeloma. BrJHaematol 2007;138:330-337. (Pubitemid 47035389)
10. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study ofpegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-3901. (Pubitemid 47477266)
11. Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007;109:2767-2772. (Pubitemid 46482069)
12. Reece DE, Rodriguez GP, Chen C, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008; 26:4777-4783.
13. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalido-mide is an inhibitor ofangiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
14. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276:22382-22387.
15. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-4530. (Pubitemid 34627223)
16. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expres-sion in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009; 69:7347-7356.
17. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98: 210-216.
18. Reddy N, Hernandez-Ilizalituri FJ, Deeb G, et al. Immuno-modulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogen-esis enhancing the anti-tumour activity of rituximab. Br J Haematol 2008;140:36-45. (Pubitemid 350233246)
19. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-386. (Pubitemid 29295864)
20. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187:1885-1892. (Pubitemid 28262451)
21. Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation ofPU.1. Blood 2006;107:3098-3105.
22. Koh KR, Janz M, Mapara MY, et al. Immunomodulatory derivative ofthalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and pro-moting myelopoiesis. Blood 2005;105:3833-3840. (Pubitemid 40656125)
23. Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003;17:41-44. (Pubitemid 36175886)
24. D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol 2001;28:597-601. (Pubitemid 33134418)
25. Ferguson G, Jensen-Pergakes K, Wilkey C, et al. Immuno-modulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor ofcyclooxygenase 2. J Clin Immunol 2007;27:210-220. (Pubitemid 46348725)
26. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in re-lapsed or refractory multiple myeloma. J Clin Oncol 2004; 22:3269-3276. (Pubitemid 41103682)
27. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008;141:41-51. (Pubitemid 351350609)
28. Richardson P, Siegel D, Baz R, et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy ofpomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. Blood 2009;114(Suppl. 1): Abstract 301.
29. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27:5008-5014.
30. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myelo-ma (MM). Leukemia 2010;24:1934-1939.
31. Kumar S, Blade J, Crowley J, et al. Natural history ofmultiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group Study. Blood2009;114(Suppl. 1): Abstract 2878.
32. Richardson PG, Siegel D, Baz R, et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. Blood 2010; 116(Suppl. 1): Abstract864.
33. Leleu X, Attal M, Moreau P, et al. Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dex-amethasone as therapy for relapsed multiple myeloma. IFM 2009-02. Blood 2010;116(Suppl. 1): Abstract 859.
34. Lacy M, Mandrekar S, Gertz MAA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. Blood 2010;116(Suppl. 1): Abstract 863.
35. Short KD, Rajkumar SV, Buadi F, et al. Increased incidence of extramedullary plasmacytomas in patients with multiple myeloma in the era of novel therapy and effect of pomalido-mide on extramedullary disease. Blood 2010;116(Suppl. 1): Abstract 3047.
36. Geyer H, Viggiano R, Lacy M, et al. Acute lung toxicity related to pomalidomide. Chest. 2011; in press.
37. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Orga-nization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
38. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24:1128-1138.
39. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-1265. (Pubitemid 30235956)
40. Gangat N, Caramazza D, Vaidya R, et al. DIPSS-plus: a refined Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis that incorporates prognos-tic information from karyotype, platelet count and transfusion status. J Clin Oncol 2010 Dec 13. [Epub ahead ofprint].
41. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Trans-plant 2010;16:358-367.
42. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 2008;83:491-497. (Pubitemid 351742799)
43. Mishchenko E, Tefferi A. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. Eur J Haematol 2010;85:192-199.
44. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-1127.
45. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy ofTG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; Published Ahead of Print on January 10, 2011 as 10.1200/JCO.2010.32.8021.
46. Tefferi A. Pathogenesis of myelofibrosis with myeloid meta-plasia. J Clin Oncol 2005;23:8520-8530.
47. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations ofbone marrow angiogen-esis in myelofibrosis with myeloid metaplasia. Blood 2000; 96:3374-3380.
48. Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A, Tefferi A. Circulating IL-2R, IL-8, IL-15 and CXCL10 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. Blood 2010; 116(Suppl. 1): Abstract 3068.
49. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-2541. (Pubitemid 36857609)
50. Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006; 106:1974-1984. (Pubitemid 43673213)
51. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108:1158-1164. (Pubitemid 44232010)
52. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009;27:4760-4766.
53. Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010;116:4436-4438.
54. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 117:288-296. (Pubitemid 34451143)
55. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497-1503. (Pubitemid 44316114)
56. Marchetti M, Barosi G, Balestri F, et al. Low-dose thalido-mide ameliorates cytopenias and splenomegaly in myelofi-brosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004;22:424-431. (Pubitemid 41079770)
57. Thapaliya P, Tefferi A, Pardanani A, et al. Inter-national working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol 2011;86:96-98.
58. Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remis-sions. Leukemia 2007;21:1827-1828. (Pubitemid 47086775)
59. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofi-brosis. J Clin Oncol 2009;27:4563-4569.
60. Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010;85:129-130.
61. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis with anemia. Leu-kemia 2010 Nov 5. [Epub ahead ofprint].